215 related articles for article (PubMed ID: 33655525)
1. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
3. Outpatient administration of high-dose methotrexate in adults without drug monitoring - a case-control study of risk factors for acute kidney injury.
Alves C; Pereira J; Rego EM; Rocha V; Silva WF
Hematol Transfus Cell Ther; 2023 Dec; ():. PubMed ID: 38233304
[TBL] [Abstract][Full Text] [Related]
4. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients.
Mosleh E; Snyder S; Wu N; Willis DN; Malone R; Hayashi RJ
Front Oncol; 2023; 13():1280587. PubMed ID: 37965460
[TBL] [Abstract][Full Text] [Related]
6. Access to Methotrexate Monitoring in Latin America: A Multicountry Survey of Supportive Care Capacity.
Villanueva G; Lowe J; Tentoni N; Taluja A; Villarroel M; Narváez CE; León SA; Valencia Libreros DL; Gonzalez Suárez N; Mikkelsen TS; Howard SC
Pediatr Hematol Oncol; 2024; 41(2):135-149. PubMed ID: 37865916
[TBL] [Abstract][Full Text] [Related]
7. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review.
Yang Y; Liu Z; Chen J; Wang X; Jiao Z; Wang Z
Eur J Clin Pharmacol; 2024 Jan; 80(1):11-37. PubMed ID: 37934204
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution.
Price L; Garrity L; Stiehl S
Pharmacotherapy; 2024 Feb; 44(2):141-148. PubMed ID: 38050327
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients.
Mosleh E; Snyder S; Wu N; Willis DN; Malone R; Hayashi RJ
Front Oncol; 2023; 13():1333273. PubMed ID: 38090499
[TBL] [Abstract][Full Text] [Related]
11. How Reliable Are Serum Levetiracetam Levels to Be Used as a Primary Endpoint?
Alshaya AI; Alhammad AM
Crit Care Med; 2024 Apr; 52(4):e203-e204. PubMed ID: 38483228
[No Abstract] [Full Text] [Related]
12. Levetiracetam-Mediated Drug-Induced Liver Injury - A Rare Presentation and Review of Literature.
Jain RS; Srivastava T; Sharma P; Pemawat A
Ann Indian Acad Neurol; 2024; 27(1):87-90. PubMed ID: 38495241
[No Abstract] [Full Text] [Related]
13. Diagnosis and Treatment of Status Epilepticus.
Lee SK
J Epilepsy Res; 2020 Dec; 10(2):45-54. PubMed ID: 33659195
[TBL] [Abstract][Full Text] [Related]
14. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid.
van der Meer PB; Dirven L; Fiocco M; Vos MJ; Kouwenhoven MCM; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
Epilepsia; 2021 May; 62(5):1119-1129. PubMed ID: 33735464
[TBL] [Abstract][Full Text] [Related]
15. [Nonconvulsive Status Epilepticus Associated with Theophylline: A Case Report].
Uemura J; Yamashita S; Kurokawa K; Yagita Y; Inoue T
Brain Nerve; 2021 Mar; 73(3):283-288. PubMed ID: 33678620
[TBL] [Abstract][Full Text] [Related]
16. Periodic electroclinical seizures following an ischemic stroke revealed by continuous-EEG.
Elmali AD; Ekizoglu E; Ciftci I; Yesilot N; Coban O; Baykan B
Epilepsy Behav Rep; 2021; 15():100428. PubMed ID: 33665600
[TBL] [Abstract][Full Text] [Related]
17. Cognitive dysfunction in Nigerian women with epilepsy on carbamazepine and levetiracetam monotherapy.
Ogunjimi L; Yaria J; Makanjuola A; Alabi A; Osalusi B; Oboh D; Olusola-Bello M; Aderinola A; Ogunniyi A
Brain Behav; 2021 Apr; 11(4):e02038. PubMed ID: 33666367
[TBL] [Abstract][Full Text] [Related]
18. Update on the management of status epilepticus.
Rossetti AO; Alvarez V
Curr Opin Neurol; 2021 Apr; 34(2):172-181. PubMed ID: 33664203
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Medication Dosage Adjustment in Hospitalized Patients With Chronic Kidney Disease.
Hassan Z; Ali I; Ullah AR; Ahmed R; Zar A; Ullah I; Rehman S; Khan AU; Ullah R; Hanif M
Cureus; 2021 Feb; 13(2):e13449. PubMed ID: 33767933
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of second line therapies in toxic seizures.
Fletcher ML; Sarangarm P; Nash J; Smolinske SC; Alunday RL; Seifert SA; Warrick BJ
Clin Toxicol (Phila); 2021 Jun; 59(6):451-456. PubMed ID: 33755521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
